Administration of recombinant human...
Administration of recombinant human Factor XIII (ZymoGenetics, Inc., Seattle, WA, rFactor XIII) to healthy presents appeared to be safe with no serious adverse marked occurrences reported. The trial was a Phase 1 single-dose escalation investigation in healthy volunteers. The cogitation was designed to evaluate the safety and pharmacokinetics of the
|